Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position

Pharmazie

Volumn 59, Issue 9, 2004, Pages 659-667

  Obreza, A ^a   Stegnar, M ^b   Urleb, Uroš ^a,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Lek dd   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGATROBAN; AZAPHENYLALANINE DERIVATIVE; BENZAMIDINE; BENZYLAMINE; BLOOD CLOTTING FACTOR 10A; LK 733; METHYL GROUP; METHYLAMINE; SERINE PROTEINASE; THROMBIN; THROMBIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; REACTION ANALYSIS;

BINDING SITES; FACTOR XA; HYDRAZINES; INDICATORS AND REAGENTS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; PHENYLALANINE; SERINE PROTEINASE INHIBITORS; THROMBIN; TRYPSIN INHIBITORS;

EID: 4644273697     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ammar HO, Ghorab M, El-Nahhas SA, Makram TS (1997) Improvement of the biological performance of oral anticoagulant drugs. 1. Warfarin. Pharmazie 52: 627-631.
2. Brandt RB, Laux JE, Yates SW (1987) Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol 37: 344.
3. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C (1997) Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 78: 1404-1407.
4. Hirsh J, Weitz JI (1999) New Antithrombotic Agents. Lancet 353: 1431-1436.
5. α- substituted-L-arginine. J Med Chem 23: 1293-1299.
6. Menear K (1998) Progress towards the discovery of orally active thrombin inhibitors. Curr Med Chem 5: 457-468.
7. Obreza A, Urleb U (2002) A new synthesis of substituted benzaldehyde N-(phenylmethylidene)hydrazones. Acta Chim Slov 49: 605-611.
8. Rewinkel JBM, Adang AEP (1999) Strategies and progress towards the ideal orally active thrombin inhibitor. Curr Pharm Des 5: 1043-1075.
9. Stone SR, Hofsteenge J (1986). Kinetics of the inhibition of thrombin by hirudin. Biochem 25: 4622-4628.
10. Stürzebecher J, Markwardt F, Voigt B, Wagner G, Walsmann P (1983) Cyclic amides of Nα-arylsulfonylaminoacylated 4-amidinophenylalanine, tight binding of thrombin. Thromb Res 29: 635-642.
11. Zega A, Mlinšek G, Šepic P, Golič Grdadolnik S, Šolmajer T, Tschopp TB, Steiner B, Kikelj D, Urleb U (2001a) Design and strucure-activity relationship of thrombin inhibitors with an azaphenylalanine scaffold: potency and selectivity enhancements via P2 optimization. Bioorg Med Chem 9: 2745-2756.
12. Zega A, Trampuš-Bakija A, Fortuna M, Stegnar M, Tschopp TB, Steiner B, Urleb U (2001b) Novel thrombin inhibitors with azaphenylalanine scaffold. Pharmazie 56: 683-685.